Dosing & Uses
Dosage Forms & Strengths
Basal Cell Carcinoma
Indicated for treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery or radiation
150 mg PO qDay
Renal & Hepatic Impairment
No dose adjustment is required in patients with renal impairment
No dose adjustment required in patients with hepatic impairment
May take with or without food
Safety and efficacy not established
Clinical trials did not include sufficient numbers of patient 65 years or older to evaluate if a different dose is required
Serious - Use Alternative
Significant - Monitor Closely
Muscle spasms (71.7%)
Weight loss (44.9%)
Decreased appetite (25.4%)
Frequency Not Defined
Premature fusion of epiphyses
Increased blood creatinine phosphokinase
Black Box Warnings
Embryo-fetal death and severe birth defects
- Can cause fetal harm when administered to a pregnant woman based on its mechanism of action
- Shown to be teratogenic, embryotoxic, and fetotoxic in rats at maternal exposures lower than the human exposures at the recommended dose of 150 mg/day; embryolethal in rats at exposures within the range achieved at the recommended human dose
- Rat malformations included craniofacial anomalies, open perineum, and absent or fused digits; fetal retardations and variations were also observed
- Verify pregnancy status prior to the initiation
- Advise male and female patients of the risks of embryo-fetal death and severe birth defects and the need for contraception during and after treatment
- Advise patients to contact their healthcare provider immediately if they suspect they (or, for males, their female partner) may be pregnant
- Report exposure during pregnancy to the Genentech Adverse Event Line at 1-888-835-2555
Can cause fetal harm when administered to pregnant women, or if pregnant women are exposed to vismodegib via seminal fluid
Patient should not donate blood while taking vismodegib or for at least 24 months after last dose
Drugs that increase gastric pH may alter solubility of vismodegib resulting in decreased bioavailability
Drugs that inhibit P-gp efflux transporter may increase systemic exposure to vismodegib and incidence of adverse effects
Premature fusion of epiphyses reported in pediatric patients exposed to drug; In some cases, fusion progressed after drug discontinuation
Advise patients not to donate blood or blood products while receiving therapy and for 7 months after final dose
Advise males not to donate semen during and for 3 months after therapy
Verify pregnancy status of females of reproductive potential within 7 days prior to initiating therapy; advise females of reproductive potential to use effective contraception during therapy and for 24 months after final dose; advise male patients to use condoms, even after a vasectomy, to avoid potential drug exposure in pregnant partners and female partners of reproductive potential during therapy and for 3 months after the final dose; advise pregnant women of the potential risk to a fetus
Pregnancy & Lactation
Pregnancy: Can cause fetal harm when administered to a pregnant woman based on its mechanism of action (by either direct exposure or exposure from seminal fluid); see Black Box Warnings
Shown to be teratogenic, embryotoxic, and fetotoxic in rats at maternal exposures lower than the human exposures at the recommended dose of 150 mg/day; embryolethal in rats at exposures within the range achieved at the recommended human dose
Lactation: Unknown whether distributed in breast milk; because of potential for serious adverse reactions in breastfed infants from therapy, advise a nursing woman that breastfeeding is not recommended during therapy and for 24 months after the final dose; a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Hedgehog (Hh) pathway inhibitor; the Hedgehog signaling pathway is important in embryogenesis, but in adults, it is mostly inactive; signaling is relayed by key proteins including Smoothened (SMO)
Hh ligand-expressing cancerous epithelial cells that are activated by the Hh signaling pathway may cause growth-promotion; vismodegib binds to and inhibits SMO, a transmembrane protein involved in Hedgehog signal transduction
Protein Bound: >99%, binds to both albumin and alpha-1-acid glycoprotein
Vd: 16.4-26.6 L
>98% of total circulating drug components are the parent drug
Minimally metabolized by oxidation, glucuronidation, and pyridine ring cleavage
Minor substrate of CYP2C9 and CYP3A4 Minor inhibitor of CYP2C8, CYP2C9, and CYP2C19
Half-life: 4 days (at steady-state)
Excretion: feces 82%, urine 4.4%
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.